RSV Vaccine

About the RSV Vaccine

Respiratory syncytial virus (RSV) is a common respiratory virus that causes infections of the lungs and breathing passages. While RSV typically causes cold-like symptoms in healthy adults, it can lead to serious lower respiratory tract disease — including bronchiolitis and pneumonia — in older adults, those with chronic cardiorespiratory conditions, and immunocompromised individuals. RSV is responsible for approximately 14,000 deaths annually in adults aged 65 and over in Europe.

The RSV vaccine (Abrysvo) was approved in the UK in 2023 for adults aged 60 and over. It is the first licensed vaccine for RSV in adults and clinical trial data demonstrates significant protection against RSV-associated lower respiratory tract disease. The NHS began offering RSV vaccination to adults aged 75 to 79 in 2024; private vaccination is available at The Vesey for those outside the current NHS programme who wish to obtain protection.

Who should have this vaccination?

• Adults aged 60 and over, particularly those with chronic lung disease (COPD, asthma, bronchiectasis), heart disease, diabetes, or immune conditions
• Those aged 75 to 79 not yet vaccinated through the NHS programme
• Carers and family members of older or vulnerable adults who wish to reduce transmission risk
• Adults aged 60 and over who wish to protect themselves ahead of the winter respiratory virus season

Vaccination schedule

The RSV vaccine (Abrysvo) is administered as a single intramuscular injection. There is currently no established booster schedule, as long-term data on duration of protection is still being gathered. The vaccine can be given at the same time as the influenza and COVID-19 vaccines, though it should be administered at a separate injection site. Our clinical team can advise on optimal timing, particularly in relation to your influenza vaccination appointment.